UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye – Yahoo…

Posted: October 13, 2022 at 1:58 am

Unity Biotechnology, Inc.

-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT/8:00 a.m. ET-

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an Investor/Analyst Day on Wednesday, October 12, 2022 at 5:00 a.m. PT/8:00 a.m. ET to discuss the current treatment landscape and unmet medical need for age-related diseases of the eye, and the potential treatment solution that UNITYs lead program, UBX1325, may provide.

Members of UNITYs senior management team and Key Opinion Leader Robert B. Bhisitkul, M.D., Ph.D., (University of California San Francisco School of Medicine) will discuss the proposed mechanism of action of UBX1325 and new preclinical data that supports the senolytic approach in retinal diseases, the most recent UBX1325 clinical data from the BEHOLD study in Diabetic Macular Edema (DME), the ENVISION study in wet Age-related Macular Degeneration (wet AMD), including details of the new 48-week long-term follow-up extension study and near-term value driving milestones.

The live webcast can be accessed in the Investors and Media section of our website, http://www.unitybiotechnology.com, under Events & Presentations or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the Investors & Media section of our website, under Events and Presentations.

About UNITYUNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITYs current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at http://www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Story continues

Source: Unity Biotechnology, Inc

More here:
UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye - Yahoo...

Related Posts